Tenaya Therapeutics, Inc. (TNYA)
| Market Cap | 156.24M +119.8% |
| Revenue (ttm) | n/a |
| Net Income | -90.60M |
| EPS | -0.59 |
| Shares Out | 217.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 565,914 |
| Open | 0.7000 |
| Previous Close | 0.7000 |
| Day's Range | 0.6850 - 0.7054 |
| 52-Week Range | 0.3600 - 2.3500 |
| Beta | 2.99 |
| Analysts | Strong Buy |
| Price Target | 5.33 (+640.28%) |
| Earnings Date | May 7, 2026 |
About TNYA
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for TNYA stock is "Strong Buy." The 12-month stock price target is $5.33, which is an increase of 640.28% from the latest price.
News
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026
Tenaya Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Three clinical-stage programs are advancing efficiently, with TN-301 showing broad preclinical efficacy and TN-201 and TN-401 progressing in gene therapy trials. The Alnylam partnership adds significant capital and pipeline depth, while upcoming data and regulatory milestones are expected to drive further value.
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy
Tenaya Therapeutics Stock Jumps After New Alnylam Deal
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) shares are up on Thursday, reflecting a positive market response to a research collaboration agreement with Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY).
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Agreement Combines Tenaya's Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Mill...
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM
Tenaya Stock Plunges After $60 Million Equity Offering
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) stock is trading lower on Friday, with a session volume of 42.39 million compared to the average volume of 3.51 million as per data from Benzinga Pro.
Tenaya Therapeutics Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...
Tenaya Therapeutics Transcript: Study Result
Initial results from the RIDGE-1 trial show TN-401 gene therapy is well tolerated and demonstrates robust molecular and early clinical efficacy in PKP2-associated ARVC, with significant reductions in arrhythmia burden and increased PKP2 protein levels. Data compare favorably to peers and support further development.
Tenaya Therapeutics Announces Proposed Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burde...
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites
Tenaya Therapeutics Transcript: Status Update
Interim data from the TN-201 MyPEAK-1 trial show robust gene expression, improved cardiac biomarkers, and significant reductions in hypertrophy and heart failure symptoms in severe HCM patients. The FDA-requested protocol amendments are minor, with no impact on timelines, and future pivotal studies remain on track for 2026.
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™ -1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy
Tenaya Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Cardiac gene therapy is advancing with novel capsids, improved manufacturing, and regulatory support, targeting both rare and prevalent diseases. Companies are focusing on safety, commercial readiness, and precision medicine, with optimism for upcoming clinical and commercial milestones.
Tenaya Therapeutics Transcript: H. C. Wainwright Genetic Medicines Virtual Conference
Two AAV9-based gene therapies, TN-201 and TN-401, are advancing in clinical development for severe genetic cardiomyopathies, with TN-201 showing promising interim results in refractory HCM patients and TN-401 set for initial data release in Q4. Robust protein quantification and careful data disclosure support their competitive positioning.
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...
Tenaya Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Significant progress was reported for both TN-201 and TN-401 gene therapy programs, with all milestones met and major data updates expected in Q4, including a late-breaker AHA presentation. The regulatory environment remains favorable, safety protocols are robust, and innovative approaches in protein measurement and AI-driven discovery are advancing the pipeline.
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti...